AN2 Therapeutics (ANTX) Other Operating Expenses (2021 - 2022)

AN2 Therapeutics (ANTX) posted quarterly Other Operating Expenses of $1.0 million for Q3 2022, up 100.0% quarter-over-quarter from $500000.0 in Q4 2021.

AN2 Therapeutics (ANTX) Other Operating Expenses (2021 - 2022) Analysis & Trends

AN2 Therapeutics (ANTX) has reported Other Operating Expenses for 2 consecutive years, with $1.0 million the latest figure, recorded in Q3 2022.

  • In Q3 2022, Other Operating Expenses changed N/A year-over-year to $1.0 million; the TTM figure through Jun 2023 stood at $1.0 million (up 100.0% YoY), while the FY2022 annual figure was $1.0 million, up 33.33% from the prior year.
  • Other Operating Expenses improved to $1.0 million in Q3 2022 per ANTX's latest filing, from $500000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $1.0 million in Q3 2022 and bottomed at $250000.0 in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 AN2 Therapeutics 226.04 Mn 226.04 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2022 1.00 Mn
Dec 31, 2021 500,000.00
Jun 30, 2021 250,000.00